Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Bifidobacterium bifidum TMC3115 Can Characteristically Influence Glucose and Lipid Profile and Intestinal Microbiota in the Middle-Aged and Elderly.

  • 2018-07-05
  • Probiotics and antimicrobial proteins 11(4)
    • Ke Wang
    • Xiaohong Yu
    • Yi Li
    • Yun Guo
    • Lin Ge
    • Fangfang Pu
    • Xinying Ma
    • Wenjing Cui
    • Francesco Marrota
    • Fang He
    • Ming Li

Study Design

Type
Clinical Trial
Sample size
n = 47
Population
47 subjects with mild hyperglycaemia and dyslipidaemia aged 45 to 75 years
Methods
Oral administration of Bifidobacterium bifidum TMC3115 for 3 weeks; blood and faecal samples collected before and after intervention
Duration
3 weeks
Funding
Unclear
  • Rigorous Journal
Bifidobacterium bifidum TMC3115 strain (TMC3115) was orally administrated to 47 subjects with mild hyperglycaemia and dyslipidaemia aged 45 to 75 years for 3 weeks. Blood samples were collected before and after intervention for profiling plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol and triglyceride concentrations, as well as fasting blood glucose. Before and 3 and 4 weeks after intervention, the faecal samples were collected to analyse faecal microbiota using the sequencing of 16S rRNA genes with a next-generation sequencer. TMC3115 significantly decreased plasma TC and LDL-C levels of the tested subjects after intervention (P < 0.05). The frequencies of defaecation and faecal odour after the intervention and 1 week later were significantly better than at pre-intervention, respectively. TMC3115 administration increased Firmicutes, Bacteroides and Actinobacteria and decreases in Proteobacteria and Fusobacteria. There were significant increases in the proportions of Dorea and Lachnospira after the intervention (P < 0.05). TMC3115 also increased the level of Firmicutes and decreased that of Bacteroidetes 1 week after the intervention (P < 0.05). Serum triglycerides correlated negatively with the proportions of Bacteroidetes (R = - 0.21, P = 0.047) and Bacteroides (R = - 0.23, P = 0.029), while the relative abundance of Dialister of Firmicutes correlated negatively and significantly with the serum LDL-C (R = - 0.24, P = 0.022) and TC levels (R = - 0.22, P = 0.030). These results indicate that TMC3115 might exhibit beneficial effects on the serum cholesterol metabolism of subjects with dyslipidaemia through modulation of their intestinal microbiota. Trial registration: ChiCTR-OOC-16010271.

Research Insights

    Back to top